Five Prime Therapeutics Announces Executive Change

Published: Mar 13, 2018

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Marc Belsky, Senior Vice President and Chief Financial Officer, has resigned to pursue another opportunity. Mr. Belsky will continue in his current role until April 6, 2018. Five Prime plans to undertake a search for a new Chief Financial Officer promptly.

“We thank Marc for his important contributions to Five Prime, including building our finance and accounting organization and leading the company through its initial public offering in 2013, as well as additional follow-on public offerings,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics. “Marc’s leadership has contributed significantly to Five Prime’s financial strength, and we wish him much success in his future endeavors.”

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and the focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit or follow us on LinkedIn, Twitter and Facebook.

Back to news